These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 33722546)

  • 1. Stability of monoclonal antibodies after simulated subcutaneous administration.
    Schuster J; Mahler HC; Joerg S; Kamuju V; Huwyler J; Mathaes R
    J Pharm Sci; 2021 Jun; 110(6):2386-2394. PubMed ID: 33722546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analytical Challenges Assessing Protein Aggregation and Fragmentation Under Physiologic Conditions.
    Schuster J; Mahler HC; Joerg S; Huwyler J; Mathaes R
    J Pharm Sci; 2021 Sep; 110(9):3103-3110. PubMed ID: 33933436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies.
    Datta-Mannan A; Estwick S; Zhou C; Choi H; Douglass NE; Witcher DR; Lu J; Beidler C; Millican R
    MAbs; 2020 Jan; 12(1):1770028. PubMed ID: 32486889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vivo Stability of Therapeutic Proteins.
    Schuster J; Koulov A; Mahler HC; Detampel P; Huwyler J; Singh S; Mathaes R
    Pharm Res; 2020 Jan; 37(2):23. PubMed ID: 31900680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking the physical stability of fluorescent-labeled mAbs under physiologic in vitro conditions in human serum and PBS.
    Schuster J; Mahler HC; Koulov A; Joerg S; Racher A; Huwyler J; Detampel P; Mathaes R
    Eur J Pharm Biopharm; 2020 Jul; 152():193-201. PubMed ID: 32371154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing Particle Formation of Biotherapeutics in Biological Fluids.
    Schuster J; Probst CE; Mahler HC; Joerg S; Huwyler J; Mathaes R
    J Pharm Sci; 2021 Apr; 110(4):1527-1532. PubMed ID: 33421437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Antibody Stability in a Novel Protein-Free Serum Model.
    Schuster J; Kamuju V; Mathaes R
    Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34067269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical Stability Studies of Antibody-Drug Conjugates (ADCs) Under Stressed Conditions.
    Adem YT
    Methods Mol Biol; 2020; 2078():301-311. PubMed ID: 31643066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physicochemical Stability of Monoclonal Antibodies: A Review.
    Le Basle Y; Chennell P; Tokhadze N; Astier A; Sautou V
    J Pharm Sci; 2020 Jan; 109(1):169-190. PubMed ID: 31465737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components.
    Kinnunen HM; Sharma V; Contreras-Rojas LR; Yu Y; Alleman C; Sreedhara A; Fischer S; Khawli L; Yohe ST; Bumbaca D; Patapoff TW; Daugherty AL; Mrsny RJ
    J Control Release; 2015 Sep; 214():94-102. PubMed ID: 26210441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site.
    Kinnunen HM; Mrsny RJ
    J Control Release; 2014 May; 182():22-32. PubMed ID: 24631859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A hydrophobic interaction chromatography method suitable for quantitating individual monoclonal antibodies contained in co-formulated drug products.
    Luo L; Jiang B; Cao Y; Xu L; Shameem M; Liu D
    J Pharm Biomed Anal; 2021 Jan; 193():113703. PubMed ID: 33147536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining the right diluent for intravenous infusion of therapeutic antibodies.
    Luo S; McSweeney KM; Wang T; Bacot SM; Feldman GM; Zhang B
    MAbs; 2020; 12(1):1685814. PubMed ID: 31774346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buffer-free therapeutic antibody preparations provide a viable alternative to conventionally buffered solutions: from protein buffer capacity prediction to bioprocess applications.
    Bahrenburg S; Karow AR; Garidel P
    Biotechnol J; 2015 Apr; 10(4):610-22. PubMed ID: 25641961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-buffering antibody formulations.
    Gokarn YR; Kras E; Nodgaard C; Dharmavaram V; Fesinmeyer RM; Hultgen H; Brych S; Remmele RL; Brems DN; Hershenson S
    J Pharm Sci; 2008 Aug; 97(8):3051-66. PubMed ID: 18023013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein Stability After Administration: A Physiologic Consideration.
    Schuster J; Kamuju V; Mathaes R
    J Pharm Sci; 2023 Feb; 112(2):370-376. PubMed ID: 36202247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model.
    Varkhede N; Forrest ML
    J Pharm Pharm Sci; 2018; 21(1s):130s-148s. PubMed ID: 30011390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations.
    Garidel P; Pevestorf B; Bahrenburg S
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):125-39. PubMed ID: 26455339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies.
    Bown HK; Bonn C; Yohe S; Yadav DB; Patapoff TW; Daugherty A; Mrsny RJ
    J Control Release; 2018 Mar; 273():13-20. PubMed ID: 29355621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.